Oncology

Advancing Personalized Medicine and Taking on the Challenge of Refractory Cancer

Our ultimate goal is to realize healthcare that spans the entire patient journey, from cancer onset through progression and recurrence to prevention. Leveraging our unique insights gained from Lenvima®, Halaven®, and Tasfygo®, we are developing innovative therapeutics through diverse drug discovery activities, such as the creation of new treatments for patients with cancers resistant to immunotherapy, treatments for difficult targets, and personalized medicine based on genetic information.

We aim to contribute to approximately 90,000 patients worldwide by advancing the combination therapy of Lenvima with Merck & Co., Rahway, NJ's anti-PD-1 therapy pembrolizumab, and expanding its oncology indications. As part of our post-Lenvima drug discovery approach, we will expand our drug discovery activities based on the human biology data of more than 10,000 cases obtained from Lenvima’s clinical trials. By analyzing this data, we aim to generate new drug discovery hypotheses and advance our programs through Eisai’s unique approach to drug development. Clinical development of CBP/β-catenin inhibitor E7386 is currently underway with particular focus on its combination with Lenvima. Through the maximization of Lenvima’s therapeutic efficacy, we will provide greater contributions to patients. Similarly, we are advancing research and development programs to create new treatment options in the oncology field. One of these efforts is a combination of Lenvima and MORAb-202, an antibody drug conjugate (ADC) that combines Halaven with a folate receptor α antibody (farletuzumab), aiming to create a new treatment with enhanced therapeutic effects and safety profile.

Please see here for our history of research and development in the oncology field.

Eisai has established long-term objectives and KPIs to monitor our progress, aiming to realize healthcare that spans the entire patient journey, from cancer onset through progression and recurrence to prevention.

Please see here for long-term objectives, KPIs, and risks in the oncology area.

Please see here for our medium-term business plan “EWAY Future & Beyond” and its progress.

Please see here for an overview of our latest major R&D pipeline for oncology.